Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story [Seeking Alpha]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Seeking Alpha
2026 is pivotal, with multiple oncology catalysts—especially Intismeran/Keytruda Phase II and III readouts—potentially driving future revenue and valuation. MRNA maintains a speculative 'Buy' rating for high-risk, long-term investors, supported by disciplined cost reductions and a maturing pipeline. Despite near-term revenue declines and cash burn, MRNA's product launches and pipeline progress underpin 10% 2026 revenue growth guidance. aprott/iStock via Getty Images Background Moderna, Inc. ( MRNA ), made their name thanks to the successful development and commercialisation of SpikeVax . However, from 2023 to date, the company has reported a sharp decline in total revenue (see image below). In This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in M
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Moderna (MRNA) Rockets 17% on Strong Preliminary FY25 Results [Yahoo! Finance]Yahoo! Finance
- The 20 stocks most shorted by hedge funds [Seeking Alpha]Seeking Alpha
- Moderna (NASDAQ:MRNA) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- Moderna (NASDAQ:MRNA) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to a "buy" rating.MarketBeat
- Commonwealth Fusion Systems Names Stephane Bancel to Board of Directors [Yahoo! Finance]Yahoo! Finance
MRNA
Earnings
- 11/6/25 - Beat
MRNA
Sec Filings
- 1/12/26 - Form 8-K
- 1/6/26 - Form 4
- 1/5/26 - Form 8-K
- MRNA's page on the SEC website